>R&D>Research Alliances

Research Alliances

(As of May 10, 2016)

 

In recent years, pharmaceutical discovery has come to require a combination of technologies from a number of specialized fields. While continuing to improve its own R&D capabilities, Takeda actively pursues alliances with other pharmaceutical manufacturers, biotechnology companies, universities, and other research institutions to efficiently introduce key technologies.

Main joint research activities

Oncology

PartnerCountryResearch subjectSchedule
Seattle Genetics US Antibody-Drug Conjugate technology Mar '09 -
Mersana Therapeutics US Antibody-Drug Conjugate technology Apr '14 -
ImmunoGen, Inc. US Antibody-Drug Conjugate technology Mar '15 -
National Cancer Center of Japan Japan

A partnership to develop basic research to clinical development by promoting exchanges among researchers, physicians, and others engaged in anti-cancer drug discovery and cancer biology research

Apr '15 - Apr '18

Gastroenterology

PartnerCountryResearch subjectSchedule

Cour Pharmaceutical Development Company

US

Immune modulating therapies for the potential treatment of celiac disease and other gastrointestinal diseases, utilizing Cour’s Tolerizing Immune Modifying nanoParticle (TIMP) platform

Dec '15 -
Enterome France

Microbiome targets thought to play crucial roles in gastrointestinal disorders, including inflammatory bowel diseases (e.g. ulcerative colitis) and motility disorders (e.g. irritable bowel syndrome).

Jan '16 -
enGene Canada

Novel therapies for specialty gastrointestinal (GI) diseases using enGene’s “Gene Pill” gene delivery platform

Jan '16 -

CNS

PartnerCountryResearch subjectSchedule

Zinfandel Pharmaceuticals

US

Alzheimer’s Disease Biomarker TOMM40

Dec '10 -
Kyoto University Japan

Treatments for obesity and schizophrenia based on CNS control

Jan '11 - Mar '16
NsGene US

Encapsulated cell therapies for the potential treatment of Parkinson’s disease

Jan '16 -

Other / Multiple Therapeutic Area

PartnerCountryResearch subjectSchedule

Tri-Institutional Therapeutics Discovery Institute

US

Collaboration of academic institutions and industry to more effectively develop innovative treatments and therapies

Oct '13 - Jun '17
Trianni, Inc. US

Trianni’s transgenic mouse platform to identify fully human monoclonal antibodies against disease targets in all therapeutic areas

Mar '14 -
MacroGenics US

Product candidates that will be directed against jointly selected pairs of molecular targets and using MacroGenics’ Dual-Affinity Re-Targeting (DART®) proprietary platform.

Sep '14 -
Keio University, Niigata University Japan

The search for and functional analysis of disease-related RNA-binding proteins, that may lead to treatments in the areas such as CNS and oncology.

Mar '15 - Mar '18

Center for iPS Cell Research Application (CiRA), Kyoto University

Japan

Clinical applications of iPS cells in areas such as heart failure, diabetes mellitus, neuro-psychiatric disorders and cancer

Apr '15 - Mar '25
Gencia LLC US

Mitochondrial Associated Glucocorticoid Receptors (MAGR) agonists for potential use primarily in hematological and inflammatory diseases

Aug '15 -